PCM
CLYM

Prelude Capital Management’s Climb Bio CLYM Stock Holding History

Prelude Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,918
Closed -$79.7K – 1659
2025
Q4 		$79.7K Sell
19,918
-20,800
-51% -$49.9K 0.01% 1211
2025
Q3 		$81.8K Buy
+40,718
New +$75.6K 0.01% 1074

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Prelude Capital Management's CLYM Position: Q1 2026 in Review

Prelude Capital Management sold out of Climb Bio (CLYM) in Q1 2026, closing a stake of 19,918 shares — an estimated $79.7K sold.

Prelude Capital Management first reported a position in CLYM in Q3 2025 and held it in 2 quarters. The position peaked at $81.8K in Q3 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Prelude Capital Management reported no remaining Climb Bio position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 19,918 Climb Bio shares in Q1 2026, an estimated $79.7K.
  • Prelude Capital Management first reported a position in Climb Bio in Q3 2025 and held it in 2 quarters.
  • Prelude Capital Management's Climb Bio position peaked at $81.8K in Q3 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.